Quest reports dip in Q4 revenues

By LabPulse.com staff writers

January 13, 2022 -- Quest Diagnostics reported preliminary results that suggest a decline in revenues for the fourth quarter of fiscal year 2021 (end-December 31). The company said that testing volumes outside of COVID-19 remain higher than they were before the pandemic.

For the period, Quest reported revenues of $2.74 billion, a decrease of 9% compared to $3 billion in 2020. The company added that total testing volume as measured by number of requisitions grew about 1.3% in the fourth quarter of 2021 versus the prior year.

The company noted that COVID-19 molecular testing volumes increased throughout the summer while its base business continued to deliver volume growth versus 2020 and 2019, showing a rebound in September.

WSJ article on rationing of COVID tests draws ire of lab specialists
An article in the Wall Street Journal claiming that clinical labs in the U.S. are limiting who has access to COVID-19 tests has drawn criticism...
Quest offers Biocept's liquid biopsy test
Quest Diagnostics has announced that it now offers the Target Selector NGS Lung Panel, a liquid biopsy test developed by molecular diagnostics firm Biocept....
Quest sees slight revenue decrease in Q3 revenues
Quest Diagnostics reported a slight decrease in revenues for the third quarter of the 2021 fiscal year.
Quest Diagnostics debuts new lab facility in NJ
Quest Diagnostics has finished integrating its Northeast regional operations into a new 25,000-sq-ft, next-generation lab facility in Clifton, NJ.
Quest, Paige to collaborate on AI software for pathology
Quest Diagnostics and Paige plan to collaborate on developing new software that will incorporate artificial intelligence (AI) and digital pathology data...

Copyright © 2022 LabPulse.com

Last Updated ls 1/13/2022 5:55:35 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current